Ironwood Pharmaceuticals Inc - Understand $irwd stock

$IRWD Market Cap: $534.5 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$378.4M

TTM

Gross Margin

Net Earnings

-$2.463M

TTM

Current Assets

$178.6M

Q3 2024

Current Liabilities

$49.38M

Q3 2024

Current Ratio

361.67%

Q3 2024

Total Assets

$389.5M

Q3 2024

Total Liabilities

$89.15M

Q3 2024

Book Value

$300.4M

Q3 2024

Cash

$88.21M

Q3 2024

P/E

-217.0

Nov 29, 2024 EST

Free Cash Flow

$119.8M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$442.7M	$410.6M	$413.8M	$389.5M	$428.4M	$346.6M	$298.3M	$274.0M	$149.6M	$76.40M	$22.88M	$150.2M	$65.87M	$43.86M	$34.30M	$18.40M	$4.600M
YoY Change	7.83%	-0.76%	6.22%	-9.08%	23.59%	16.21%	8.86%	83.16%	95.81%	233.9%	-84.77%	128.09%	50.19%	27.86%	86.41%	300.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$442.7M	$410.6M	$413.8M	$389.5M	$428.4M	$346.6M	$298.3M	$274.0M	$149.6M	$76.40M	$22.88M	$150.2M	$65.87M	$43.86M	$34.30M	$18.40M	$4.600M
Cost Of Revenue		$0.00	$0.00	$3.136M	$23.88M	$32.75M	$19.10M	$1.900M	$0.00	$25.60M	$7.203M	$965.0K	$0.00
Gross Profit		$410.6M	$413.8M	$386.4M	$404.5M	$313.9M	$279.2M	$272.1M	$149.5M	$50.90M	$15.68M	$149.3M	$65.90M
Gross Profit Margin		100.0%	100.0%	99.19%	94.43%	90.55%	93.6%	99.31%	99.93%	66.62%	68.52%	99.36%	100.04%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Selling, General & Admin	$158.3M	$116.0M	$111.1M	$140.0M	$172.5M	$219.7M	$231.2M	$173.3M	$125.2M	$118.3M	$123.2M	$92.54M	$45.92M	$27.17M	$19.00M	$15.30M	$8.900M
YoY Change	36.48%	4.37%	-20.62%	-18.82%	-21.5%	-4.98%	33.4%	38.42%	5.83%	-4.0%	33.16%	101.52%	69.02%	42.99%	24.18%	71.91%	23.61%
% of Gross Profit		28.25%	26.86%	36.23%	42.63%	69.99%	82.81%	63.69%	83.75%	232.42%	785.99%	61.99%	69.68%
Research & Development	$116.1M	$44.27M	$70.41M	$88.06M	$115.0M	$101.1M	$88.15M	$139.5M	$108.7M	$101.9M	$102.4M	$113.5M	$86.09M	$77.45M	$76.10M	$51.40M	$50.40M
YoY Change	162.25%	-37.13%	-20.05%	-23.45%	13.84%	14.65%	-36.81%	28.33%	6.67%	-0.47%	-9.78%	31.8%	11.15%	1.78%	48.05%	1.98%	70.27%
% of Gross Profit		10.78%	17.02%	22.79%	28.44%	32.2%	31.57%	51.27%	72.71%	200.2%	653.0%	76.01%	130.64%
Depreciation & Amortization	$1.200M	$1.400M	$1.500M	$2.300M	$5.600M	$3.900M	$6.400M	$11.30M	$11.60M	$12.30M	$11.73M	$11.33M	$9.999M	$6.161M	$4.800M	$2.600M	$1.700M
YoY Change	-14.29%	-6.67%	-34.78%	-58.93%	43.59%	-39.06%	-43.36%	-2.59%	-5.69%	4.87%	3.57%	13.26%	62.3%	28.35%	84.62%	52.94%	30.77%
% of Gross Profit		0.34%	0.36%	0.6%	1.38%	1.24%	2.29%	4.15%	7.76%	24.17%	74.81%	7.59%	15.17%
Operating Expenses	$274.4M	$160.3M	$181.5M	$228.1M	$287.5M	$320.7M	$319.3M	$323.5M	$234.0M	$220.2M	$225.6M	$206.0M	$132.0M	$104.6M	$95.10M	$66.70M	$59.30M
YoY Change	71.22%	-11.72%	-20.4%	-20.67%	-10.36%	0.44%	-1.29%	38.25%	6.27%	-2.4%	9.51%	56.05%	26.18%	10.01%	42.58%	12.48%	61.58%
Operating Profit	-$945.4M	$250.3M	$232.3M	$142.9M	$120.1M	-$150.7M	-$15.36M	-$51.40M	-$84.50M	-$169.3M	-$252.0M	-$72.76M	-$66.14M	-$60.77M
YoY Change	-477.66%	7.78%	62.49%	18.99%	-179.73%	880.73%	-70.11%	-39.17%	-50.09%	-32.82%	246.34%	10.01%	8.85%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Interest Expense	$21.63M	$7.598M	$31.15M	$29.48M	$36.60M	$37.72M	$36.37M	-$29.80M	-$40.60M	-$20.90M	$21.00M	$59.00K	$63.00K	$196.0K	-$100.0K	$1.800M	$3.600M
YoY Change	184.67%	-75.61%	5.67%	-19.46%	-2.97%	3.72%	-222.05%	-26.6%	94.26%	-199.51%	35496.61%	-6.35%	-67.86%	-296.0%	-105.56%	-50.0%	71.43%
% of Operating Profit		3.04%	13.41%	20.62%	30.47%
Other Income/Expense, Net	-$2.639M	$2.085M	-$31.60M	-$34.08M	-$61.18M	-$43.48M	-$39.55M		$0.00	$700.0K	-$20.81M	$138.0K	$1.293M	$1.411M	$600.0K	-$900.0K	$600.0K
YoY Change	-226.57%	-106.6%	-7.27%	-44.3%	40.72%	9.92%			-100.0%	-103.36%	-15179.71%	-89.33%	-8.36%	135.17%	-166.67%	-250.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Pretax Income	-$948.1M	$252.4M	$200.7M	$108.9M	$58.94M	-$194.1M	-$54.90M	-$81.70M	-$142.7M	-$189.6M	-$272.8M	-$72.62M	-$64.85M	-$59.36M	-$60.30M	-$47.40M	-$50.40M
YoY Change	-475.59%	25.8%	84.32%	84.69%	-130.36%	253.64%	-32.8%	-42.75%	-24.74%	-30.5%	275.65%	11.99%	9.26%	-1.57%	27.22%	-5.95%	45.66%
Income Tax	$83.49M	$77.36M	-$327.8M	$2.685M	$0.00	$0.00	$0.00			$0.00	$0.00	$0.00	$3.000K	-$2.944M	-$300.0K	$0.00	$0.00
% Of Pretax Income		30.65%	-163.36%	2.47%	0.0%
Net Earnings	-$1.002B	$175.1M	$528.4M	$106.2M	$21.51M	-$282.4M	-$116.9M	-$81.70M	-$142.7M	-$189.6M	-$272.8M	-$72.62M	-$64.85M	-$51.86M	-$71.20M	-$53.90M	-$52.80M
YoY Change	-672.5%	-66.87%	397.71%	393.73%	-107.62%	141.47%	43.13%	-42.75%	-24.74%	-30.5%	275.63%	11.98%	25.05%	-27.16%	32.1%	2.08%	41.94%
Net Earnings / Revenue	-226.37%	42.64%	127.72%	27.26%	5.02%	-81.46%	-39.2%	-29.82%	-95.39%	-248.17%	-1192.26%	-48.34%	-98.45%	-118.25%	-207.58%	-292.93%	-1147.83%
Basic Earnings Per Share	-$6.45	$1.13	$3.26	$0.67	$0.14	-$1.85					-$2.35	-$0.68	-$0.65
Diluted Earnings Per Share	-$6.45	$0.96	$3.21	$0.66	$0.14	-$1.85	-$784.6K	-$563.8K	-$1.004M	-$1.386M	-$2.35	-$0.68	-$0.65	-$590.9K	-$10.03M	-$7.812M	-$7.881M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Cash & Short-Term Investments	$92.15M	$656.2M	$620.1M	$362.6M	$177.0M	$173.2M	$221.4M	$305.2M	$439.4M	$248.3M	$197.6M	$168.2M	$164.0M	$248.0M	$122.3M	$89.80M	$91.90M
YoY Change	-85.96%	5.82%	71.02%	104.86%	2.19%	-21.77%	-27.46%	-30.54%	76.96%	25.66%	17.48%	2.56%	-33.87%	102.78%	36.19%	-2.29%
Cash & Equivalents	$92.15M	$656.2M	$620.1M	$362.6M	$177.0M	$173.2M	$125.7M	$54.00M	$261.3M	$74.30M	$75.50M	$113.9M	$77.20M	$39.20M	$120.6M	$67.70M	$62.40M
Short-Term Investments						$0.00	$95.70M	$251.2M	$178.1M	$174.0M	$122.1M	$31.50M	$76.70M	$203.7M	$0.00	$22.00M	$29.50M
Other Short-Term Assets	$12.01M	$8.965M	$11.05M	$10.90M	$12.00M	$12.40M	$7.300M	$9.000M	$6.300M	$9.200M	$6.200M	$8.000M	$2.900M	$8.100M	$4.000M	$11.20M	$1.700M
YoY Change	33.99%	-18.9%	1.41%	-9.17%	-3.23%	69.86%	-18.89%	42.86%	-31.52%	48.39%	-22.5%	175.86%	-64.2%	102.5%	-64.29%	558.82%
Inventory					$600.0K	$0.00	$700.0K	$1.100M	$0.00	$5.000M	$22.10M	$6.700M	$0.00
Prepaid Expenses
Receivables	$129.1M	$115.5M	$114.0M	$122.4M	$117.2M	$81.00M	$82.20M	$64.90M	$54.50M	$25.80M	$3.200M	$1.500M	$700.0K	$2.900M	$5.200M	$4.800M	$25.50M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$233.3M	$780.6M	$745.2M	$495.8M	$306.9M	$266.4M	$311.6M	$380.2M	$500.2M	$288.3M	$229.1M	$184.4M	$167.6M	$259.1M	$131.4M	$105.7M	$119.2M
YoY Change	-70.12%	4.75%	50.31%	61.55%	15.2%	-14.51%	-18.04%	-23.99%	73.5%	25.84%	24.24%	10.02%	-35.31%	97.18%	24.31%	-11.33%
Property, Plant & Equipment	$18.17M	$20.31M	$22.93M	$25.50M	$30.20M	$17.30M	$17.30M	$20.50M	$21.10M	$29.80M	$37.40M	$37.50M	$33.60M	$34.40M	$21.80M	$24.60M	$4.100M
YoY Change	-10.54%	-11.4%	-10.1%	-15.56%	74.57%	0.0%	-15.61%	-2.84%	-29.19%	-20.32%	-0.27%	11.61%	-2.33%	57.8%	-11.38%	500.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$215.9M	$285.0M	$334.8M	$14.50M	$32.30M	$47.60M	$116.1M	$142.2M	$97.80M	$11.20M	$12.50M	$7.900M	$7.800M	$7.900M	$9.200M	$8.000M	$12.60M
YoY Change	-24.23%	-14.87%	2208.82%	-55.11%	-32.14%	-59.0%	-18.35%	45.4%	773.21%	-10.4%	58.23%	1.28%	-1.27%	-14.13%	15.0%	-36.51%
Total Long-Term Assets	$237.8M	$319.9M	$381.7M	$63.40M	$95.80M	$65.70M	$294.1M	$329.6M	$118.9M	$41.00M	$49.90M	$45.50M	$41.40M	$42.30M	$31.10M	$32.70M	$16.70M
YoY Change	-25.67%	-16.19%	502.05%	-33.82%	45.81%	-77.66%	-10.77%	177.21%	190.0%	-17.84%	9.67%	9.9%	-2.13%	36.01%	-4.89%	95.81%
Total Assets	$471.1M	$1.101B	$1.127B	$559.2M	$402.7M	$332.1M	$605.7M	$709.8M	$619.1M	$329.3M	$279.0M	$229.9M	$209.0M	$301.4M	$162.5M	$138.4M	$135.9M
YoY Change
Accounts Payable	$7.830M	$483.0K	$935.0K	$700.0K	$5.500M	$18.10M	$16.00M	$17.70M	$8.600M	$9.800M	$10.20M	$21.70M	$6.400M	$4.300M	$4.800M	$3.700M	$5.600M
YoY Change	1521.12%	-48.34%	33.57%	-87.27%	-69.61%	13.13%	-9.6%	105.81%	-12.24%	-3.92%	-53.0%	239.06%	48.84%	-10.42%	29.73%	-33.93%
Accrued Expenses	$67.47M	$25.02M	$42.59M	$31.50M	$34.60M	$53.50M	$45.60M	$45.20M	$27.50M	$26.20M	$21.90M	$26.80M	$18.10M	$17.10M	$16.70M	$14.00M	$7.500M
YoY Change	169.62%	-41.25%	35.2%	-8.96%	-35.33%	17.32%	0.88%	64.36%	4.96%	19.63%	-18.28%	48.07%	5.85%	2.4%	19.29%	86.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$199.6M	$0.00	$116.9M		$0.00	$47.60M	$4.100M	$6.200M	$27.60M	$12.40M	$1.100M	$300.0K	$200.0K	$200.0K	$1.100M	$1.100M	$1.000M
YoY Change		-100.0%			-100.0%	1060.98%	-33.87%	-77.54%	122.58%	1027.27%	266.67%	50.0%	0.0%	-81.82%	0.0%	10.0%
Total Short-Term Liabilities	$276.1M	$25.53M	$161.7M	$32.20M	$40.90M	$119.5M	$66.00M	$91.10M	$76.50M	$60.50M	$41.00M	$54.90M	$65.10M	$64.40M	$56.40M	$36.80M	$29.90M
YoY Change	981.69%	-84.21%	402.17%	-21.27%	-65.77%	81.06%	-27.55%	19.08%	26.45%	47.56%	-25.32%	-15.67%	1.09%	14.18%	53.26%	23.08%
Long-Term Debt	$498.3M	$396.3M	$337.3M	$430.3M	$408.0M	$366.3M	$396.1M	$366.6M	$353.9M	$160.7M	$177.8M	$300.0K	$400.0K	$400.0K	$900.0K	$1.100M	$2.000M
YoY Change	25.76%	17.47%	-21.61%	5.47%	11.38%	-7.52%	8.05%	3.59%	120.22%	-9.62%	59166.67%	-25.0%	0.0%	-55.56%	-18.18%	-45.0%
Other Long-Term Liabilities	$42.96M	$26.37M	$21.99M	$34.20M	$47.10M	$42.60M	$133.7M	$185.4M	$93.60M	$19.50M	$21.90M	$30.60M	$33.60M	$77.00M	$105.1M	$57.50M	$58.60M
YoY Change	62.94%	19.92%	-35.72%	-27.39%	10.56%	-68.14%	-27.89%	98.08%	380.0%	-10.96%	-28.43%	-8.93%	-56.36%	-26.74%	82.78%	-1.88%
Total Long-Term Liabilities	$541.3M	$422.6M	$359.3M	$464.5M	$455.1M	$408.9M	$529.8M	$552.0M	$447.5M	$180.2M	$199.7M	$30.90M	$34.00M	$77.40M	$106.0M	$58.60M	$60.60M
YoY Change	28.08%	17.62%	-22.64%	2.07%	11.3%	-22.82%	-4.02%	23.35%	148.34%	-9.76%	546.28%	-9.12%	-56.07%	-26.98%	80.89%	-3.3%
Total Liabilities	$817.4M	$448.1M	$521.0M	$496.6M	$496.0M	$528.4M	$595.8M	$643.1M	$524.0M	$240.8M	$240.7M	$85.90M	$99.10M	$141.8M	$165.7M	$100.7M	$97.00M
YoY Change	82.39%	-13.99%	4.92%	0.12%	-6.13%	-11.31%	-7.35%	22.73%	117.61%	0.04%	180.21%	-13.32%	-30.11%	-14.42%	64.55%	3.81%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018
Basic Shares Outstanding	155.4M	154.4M	162.2M	159.4M	156.0M	152.6M
Diluted Shares Outstanding	155.4M	186.3M	164.4M	160.7M	156.0M	152.6M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $534.49 Million

About IRONWOOD PHARMACEUTICALS INC

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 267 full-time employees. The company went IPO on 2010-02-03. The company is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. The company is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. The company is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. The company is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Industry: Pharmaceutical Preparations Peers: AGIOS PHARMACEUTICALS, INC. Allogene Therapeutics, Inc. Travere Therapeutics, Inc. IOVANCE BIOTHERAPEUTICS, INC. Krystal Biotech, Inc. Lyell Immunopharma, Inc. MYRIAD GENETICS INC Revolution Medicines, Inc. RECURSION PHARMACEUTICALS, INC.